Stablecoin Development CORP (NBY) — SEC Filings

Q: What are the key financial highlights for Stablecoin Development CORP?

Key financial highlights for Stablecoin Development CORP are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Stablecoin Development CORP?

Key executives at Stablecoin Development CORP are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Stablecoin Development CORP stock?

Risk factors for Stablecoin Development CORP (NBY) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Stablecoin Development CORP?

Forward-looking statements and predictions from Stablecoin Development CORP are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Stablecoin Development CORP. Recent 8-K filing on Apr 6, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Stablecoin Development CORP on SEC EDGAR

Overview

Stablecoin Development CORP (NBY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 6, 2026: Stablecoin Development Corp. filed an 8-K on April 6, 2026, reporting results of operations and financial condition. The filing includes financial statements and exhibits, with the primary document being the 8-K itself, filed in iXBRL format.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 42 neutral, 2 mixed. The dominant filing sentiment for Stablecoin Development CORP is neutral.

Filing Type Overview

Stablecoin Development CORP (NBY) has filed 23 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 11 DEFA14A, 1 SC 13G/A, 3 S-1/A, 2 S-1, 1 8-K/A with the SEC between Apr 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

Stablecoin Development Corp. Files 8-K on Financials — 8-K · Apr 6, 2026 Risk: low
Stablecoin Development Corp. filed an 8-K on April 6, 2026, reporting results of operations and financial condition. The filing includes financial statements an
NovaBay Pivots to Profit Amid Divestitures, Eyes Blockchain — 10-Q · Nov 7, 2025 Risk: high
NovaBay Pharmaceuticals, Inc. reported a net income of $4.455 million for the nine months ended September 30, 2025, a significant improvement from a net loss of
NovaBay Pharmaceuticals Files 8-K — 8-K · Oct 22, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on October 22, 2025, reporting an event on October 16, 2025. The filing indicates "Other Events" and "Financial State
NovaBay Pharmaceuticals Files 8-K — 8-K · Oct 21, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on October 21, 2025, reporting on events that occurred on October 20, 2025. The filing primarily concerns "Other Even
NovaBay Pharmaceuticals Files 8-K with Key Corporate Changes — 8-K · Oct 20, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an 8-K on October 20, 2025, reporting events as of October 16, 2025. The filing indicates several key items including entry
NovaBay Pharmaceuticals Reports Board and Compensation Changes — 8-K · Oct 9, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. announced on October 9, 2025, a change in its board of directors and executive compensation arrangements. The filing details the d
NovaBay Pivots from Liquidation with $6M Lazar Investment, Seeks Major Shareholder Approvals — DEF 14A · Sep 23, 2025 Risk: high
NovaBay Pharmaceuticals, Inc. (NBY) is seeking stockholder approval for a series of critical proposals at its 2025 Annual Meeting on October 16, 2025, primarily
NovaBay Pharmaceuticals Files 8-K — 8-K · Sep 18, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on September 18, 2025, to report current information. The filing does not contain specific financial details or mater
NovaBay Pharmaceuticals Files 8-K — 8-K · Aug 26, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on August 26, 2025, reporting other events and financial statements. The filing does not contain specific details abo
NovaBay Pharmaceuticals Reports Material Events — 8-K · Aug 19, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an 8-K on August 19, 2025, reporting several material events. These include entering into a definitive agreement, unregister
NovaBay Swings to Profit on Divestitures, Eyes Liquidation or New Strategy — 10-Q · Aug 14, 2025 Risk: high
NovaBay Pharmaceuticals, Inc. (NBY) reported a net income of $5.748 million for the six months ended June 30, 2025, a significant turnaround from a net loss of
NovaBay Pharmaceuticals Q1 2025 Revenue at $5.5M — 10-Q · May 15, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed its Q1 2025 10-Q report on May 15, 2025, detailing financial performance for the quarter ending March 31, 2025. The company
NovaBay Pharmaceuticals Submits Matters to Security Holders — 8-K · Apr 22, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an 8-K on April 22, 2025, reporting that on April 16, 2025, matters were submitted to a vote of its security holders. The fi
NovaBay Pharmaceuticals Files 2024 10-K — 10-K · Apr 2, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed its 2024 10-K on April 2, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Delaware
NovaBay Pharmaceuticals Files 2025 Proxy Statement — DEF 14A · Mar 19, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed its definitive proxy statement on March 19, 2025, for its annual meeting of stockholders scheduled for April 16, 2025. The f
NovaBay Pharmaceuticals Enters Material Definitive Agreement — 8-K · Mar 11, 2025 Risk: medium
On March 5, 2025, NovaBay Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with IRS number 680454536, f
NovaBay Pharma Files Proxy Solicitation Material — DEFA14A · Mar 7, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed a DEFA14A on March 7, 2025, related to a previous 8-K filing from March 4, 2025. This filing is soliciting material under Ru
NovaBay Pharma Files DEFA14A for Soliciting Material — DEFA14A · Feb 4, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed a DEFA14A on February 4, 2025, related to soliciting material under Rule 14a-12 of the Exchange Act. The filing indicates th
NovaBay Sells Eyecare Business, Adjourns Shareholder Meeting — DEFA14A · Jan 23, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed a DEFA14A on January 23, 2025, announcing the completion of its Eyecare business sale to PRN. The company also announced the
NovaBay Pharma CFO Departs, Interim Appointed; New Directors Elected — 8-K · Jan 22, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on January 15, 2025, the departure of its Chief Financial Officer, Mark J. Watson III. The company has appointed Dr. Jus
NovaBay Pharmaceuticals Completes Acquisition of 03 Life Sciences — 8-K · Jan 10, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on January 3, 2025, the completion of its acquisition of 03 Life Sciences. The filing details the entry into a material
NovaBay Pharmaceuticals Files 8-K — 8-K · Dec 19, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on December 19, 2024, reporting on matters submitted to a vote of security holders, other events, and financial state
NovaBay Pharma Stockholder Meeting Vote Urgently Needed — DEFA14A · Dec 11, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on December 11, 2024, regarding its reconvened Special Meeting of Stockholders.
NovaBay CEO Urges FOR Vote at Special Meeting — DEFA14A · Dec 9, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. (NBY) has filed a Definitive Additional Materials proxy statement (DEFA14A) on December 9, 2024. The filing includes a letter from
NovaBay Pharmaceuticals Special Meeting Adjourned — DEFA14A · Nov 26, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. filed a Definitive Additional Materials document (DEFA14A) on November 26, 2024, regarding a special meeting of stockholders. The
NovaBay Pharmaceuticals Files 8-K on Shareholder Vote & Other Events — 8-K · Nov 22, 2024 Risk: medium
On November 22, 2024, NovaBay Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security h
ISS Backs NovaBay's Avenova Sale Proposals — DEFA14A · Nov 15, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed a DEFA14A on November 15, 2024, related to its upcoming shareholder meeting. The filing highlights that the prominent proxy
NovaBay Pharmaceuticals Urges Shareholder Vote — DEFA14A · Nov 13, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on November 13, 2024, related to its proxy statement. The filing indicates that
NovaBay Urges Shareholders to Vote — DEFA14A · Nov 12, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on November 12, 2024, reminding shareholders to vote their shares. The filing ur
SC 13G/A Filing — SC 13G/A · Nov 8, 2024
NovaBay Pharma Q3 2024: Focus on Financing and Divestitures — 10-Q · Nov 7, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. filed its Q3 2024 10-Q report on November 7, 2024, for the period ending September 30, 2024. The company reported on its financial
NovaBay Pharmaceuticals Files Proxy Materials — DEFA14A · Nov 6, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on November 6, 2024. This filing relates to materials provided to shareholders,
NovaBay Pharmaceuticals Files DEFA14A — DEFA14A · Oct 29, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on October 29, 2024. This filing is related to their proxy statement and indicat
NovaBay Pharmaceuticals to be Acquired by Deerfield Management — 8-K · Oct 16, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on October 16, 2024, that it has entered into a definitive agreement to be acquired by Deerfield Management Company, L.P
NovaBay Pharmaceuticals Enters Material Definitive Agreement — 8-K · Sep 20, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on September 19, 2024, that it has entered into a Material Definitive Agreement. The company also disclosed costs associ
NovaBay Pharmaceuticals Q2 2024: Warrant Offerings Detailed — 10-Q · Aug 13, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. reported its Q2 2024 results, ending June 30, 2024. The company's financial performance and operational updates were detailed in t
NovaBay Pharmaceuticals Files 8-K — 8-K · Jul 29, 2024 Risk: medium
On July 26, 2024, NovaBay Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported other events and filed financial stateme
NovaBay Pharmaceuticals Files S-1/A Amendment — S-1/A · Jul 25, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an S-1/A amendment on July 24, 2024, for a registration statement under the Securities Act of 1933. The filing, with registr
NovaBay Pharmaceuticals Files S-1/A Amendment — S-1/A · Jul 15, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an S-1/A amendment on July 15, 2024, for its registration statement. The filing, with registration number 333-280423, indica
NovaBay Pharmaceuticals Files 8-K Report — 8-K · Jul 11, 2024 Risk: low
On July 11, 2024, NovaBay Pharmaceuticals, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of op
NovaBay Pharmaceuticals Files S-1/A Amendment — S-1/A · Jul 10, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an S-1/A amendment on July 10, 2024, to its registration statement. The filing pertains to the company's securities and is r
NovaBay Pharmaceuticals Files S-1 for Stock Offering — S-1 · Jun 21, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an S-1 registration statement on June 21, 2024, to register an unspecified amount of common stock. The company, headquartere
NovaBay Pharmaceuticals Files S-1 for Stock Offering — S-1 · Jun 20, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an S-1 registration statement on June 20, 2024, to register an unspecified number of shares of its common stock. The company
NovaBay Pharmaceuticals Files 8-K — 8-K · Jun 14, 2024 Risk: medium
On June 14, 2024, NovaBay Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securiti
NovaBay Pharmaceuticals Faces Delisting Notice — 8-K · Jun 7, 2024 Risk: high
NovaBay Pharmaceuticals, Inc. filed an 8-K on June 7, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The earliest event r
NovaBay Pharmaceuticals Files 8-K/A Amendment — 8-K/A · May 31, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K/A on May 31, 2024, to amend a previous filing regarding financial statements and exhibits. The original event date wa
NovaBay Pharmaceuticals Faces Delisting Concerns — 8-K · May 29, 2024 Risk: high
NovaBay Pharmaceuticals, Inc. filed an 8-K on May 29, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The earliest event re
NovaBay Pharmaceuticals, Inc. Files 10-Q for Q1 2024 — 10-Q · May 9, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. (NBY) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. NovaBay Pharmaceuticals reported $0.01 EPS for Q1 2024. Total r
NovaBay Pharmaceuticals Files 8-K — 8-K · Apr 22, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on April 22, 2024, to report other events and financial statements. The filing does not contain specific details abou
NovaBay Pharmaceuticals Faces Delisting Notice — 8-K · Apr 19, 2024 Risk: high
NovaBay Pharmaceuticals, Inc. filed an 8-K on April 19, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is als

Risk Profile

Risk Assessment: Of NBY's 49 recent filings, 6 were flagged as high-risk, 25 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Stablecoin Development CORP's most recent 10-Q filing (Nov 7, 2025):

Revenue: $521,000
Net Income: $4.455 million
EPS: N/A
Debt-to-Equity: 1.67
Cash Position: $2.309 million
Operating Margin: -1235.5%
Total Assets: $3.487 million
Total Debt: $1.853 million

Key Executives

Board of Directors
David E. Lazar
Paul E. Freiman
Swan Sit
Chief Executive Officer
Mark J. Watson III
Dr. Justin Hall
Dr. David J. Glick
Mr. Steven R. Smith
CEO
Justin M. Hall
Abby E. Brown

Industry Context

NovaBay Pharmaceuticals is undergoing a significant strategic transformation, divesting its established eyecare and skincare businesses. The company is now pivoting towards emerging financial infrastructure and blockchain-based markets. This sector is characterized by rapid innovation, high growth potential, and significant regulatory uncertainty, with established players and new entrants constantly vying for market share.

Top Tags

proxy-statement (10) · pharmaceuticals (8) · regulatory-filing (7) · corporate-governance (7) · financials (6) · 8-k (4) · 8-K (4) · material-agreement (4) · shareholder-vote (4) · regulatory (3)

Key Numbers

CIK Number: 0001389545 — Identifies Stablecoin Development Corp. in SEC filings.
Filing Date: 2026-04-06 — Date the 8-K was accepted by the SEC.
Net income: $4.455M — for the nine months ended September 30, 2025, compared to a $6.011M net loss in 2024
Net income from discontinued operations: $11.082M — for the nine months ended September 30, 2025, up from $841K in 2024
Product revenue, net: $521K — from continuing operations for the nine months ended September 30, 2025
Operating loss: $6.437M — from continuing operations for the nine months ended September 30, 2025
Cash and cash equivalents: $2.309M — as of September 30, 2025, up from $430K at December 31, 2024
Impairment of long-lived assets: $676K — for the nine months ended September 30, 2025
Shares of common stock outstanding: 126,010,749 — as of November 4, 2025
Reverse stock split: 1-for-35 — effected on May 30, 2024
Net proceeds from Series D Preferred Stock issuance: $3.786M — for the nine months ended September 30, 2025
Dividend paid: $4.815M — for the nine months ended September 30, 2025
Aggregate investment by David E. Lazar: $6.0 million — Total potential gross proceeds from the Investment Transaction
Gross proceeds from First Closing: $3.85 million — Received from the sale of Series D Preferred Stock
Additional gross proceeds from Final Closing: $2.15 million — Expected from the sale of Series E Preferred Stock, contingent on Proposal Five approval

Related Companies

NBAY

Frequently Asked Questions

What are the latest SEC filings for Stablecoin Development CORP (NBY)?

Stablecoin Development CORP has 50 recent SEC filings from Apr 2024 to Apr 2026, including 23 8-K, 11 DEFA14A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of NBY filings?

Across 50 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 42 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Stablecoin Development CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Stablecoin Development CORP (NBY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Stablecoin Development CORP?

Key financial highlights from Stablecoin Development CORP's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for NBY?

The investment thesis for NBY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Stablecoin Development CORP?

Key executives identified across Stablecoin Development CORP's filings include Board of Directors, David E. Lazar, Paul E. Freiman, Swan Sit, Chief Executive Officer and 7 others.

What are the main risk factors for Stablecoin Development CORP stock?

Of NBY's 49 assessed filings, 6 were flagged high-risk, 25 medium-risk, and 18 low-risk.

What are recent predictions and forward guidance from Stablecoin Development CORP?

Forward guidance and predictions for Stablecoin Development CORP are extracted from SEC filings as they are enriched.